Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Probmet Therapeutics logo — An oncology therapeutics company developing new targeted tre...

Probmet Therapeutics

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients.

Founded 2022 Denmark Denmark 2 employees Convertible Note Total: $500.00K Health Care, Health and Wellness

General Information

Company Name Probmet Therapeutics
Founded Year 2022
Location Denmark Denmark
Employees 2
Industries Health Care, Health and Wellness
Funding Stage Convertible Note
Business Model B2B, B2D
Revenue Model Licensing, Product Sales, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Probmet Therapeutics. To contact Probmet Therapeutics, visit probmet.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Probmet Therapeutics compare?

A PDF of Probmet Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Probmet Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Probmet Therapeutics

Probmet Therapeutics, headquartered in Denmark, is making strides in the field of precision oncology with a focus on developing new therapies for metastatic breast cancer in the brain. Founded in 2022, the company operates within the Health Care and Health and Wellness industries. Its core mission revolves around a critical unmet medical need, as existing treatments for breast cancer brain metastases are severely limited.

With a keen focus on innovation, Probmet Therapeutics aims to pioneer targeted treatments that could significantly alter the treatment landscape for patients afflicted by this challenging condition. Their proactive approach attracted a €500.00K Convertible Note investment from the BioInnovation Institute on 15 March 2022. This substantial funding underscores investor confidence in their vision and potential to create impactful therapeutic interventions.

Business keywords: Oncology Therapeutics, Targeted Treatments, Breast Cancer, Brain Metastasis, Precision Medicine, Metastatic Cancer, Therapeutic Development, Innovation in Cancer Treatment, Breakthrough Therapies, Neuroscience Oncology, Cancer Research, Pharmaceuticals

Services & Products

Targeted Cancer Treatments
Drug Discovery and Development
Clinical Trial Research
Biomarker Strategy

Target Customers

Breast Cancer Patients with Brain Metastasis Oncologists and Clinical Researchers Pharmaceutical and Biotech Companies

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note €500.00K 1
BioInnovation Institute
BioInnovation Institute
15 Mar 2022

Probmet Therapeutics Alternatives & Competitors

View All Alternatives
Probmet Therapeutics vs
Mersana Therapeutics
Mersana Therapeutics United States

Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fi...

Acquired
159 employees
Biotechnology, Health Care
Probmet Therapeutics vs
BeyondSpring
BeyondSpring United States

Based in Duncan, South Carolina, we are a pioneering biotechnology company dedicated to advancing he...

Series A
51 employees
Biopharma, Health Care
Probmet Therapeutics vs
NextPoint Therapeutics, Inc.
NextPoint Therapeutics, Inc.

Launching a new world of precision therapeutics through its leading scientific work on the novel B7...

38 employees
Biotechnology, Health Care
Also compare with: Probmet Therapeutics vs Faeth Therapeutics Faeth Therapeutics View all alternatives

FAQ About Probmet Therapeutics

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastatic patients.
Probmet Therapeutics was founded in 2022.
Probmet Therapeutics is headquartered in Denmark.
Probmet Therapeutics operates in Health Care and Health and Wellness. Its work centres on Oncology Therapeutics, Targeted Treatments, Breast Cancer and Brain Metastasis. Its customers include Breast Cancer Patients with Brain Metastasis, Oncologists and Clinical Researchers and Pharmaceutical and Biotech Companies.
Probmet Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing, Product Sales and Performance Based.
Probmet Therapeutics has approximately 2 employees.
Probmet Therapeutics has completed 1 funding round, raising a total of $500.00K. The latest funding stage is Convertible Note.
Probmet Therapeutics offers: Targeted Cancer Treatments, Drug Discovery and Development, Clinical Trial Research, Biomarker Strategy.
Top alternatives and competitors to Probmet Therapeutics include Mersana Therapeutics, BeyondSpring, NextPoint Therapeutics, Inc., Phoenix Molecular Designs, Radionetics Oncology. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Probmet Therapeutics and Mersana Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Probmet Therapeutics, https://bouncewatch.com/company/probmet, updated 14 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes